Mode
Text Size
Log in / Sign up

Bacterial lysates reduce exacerbation risk and hospitalization in patients with chronic obstructive pulmonary diseaseBacterial lysates may lower hospital risk for COPD patients

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider bacterial lysates to reduce exacerbation risk and hospitalization in patients with chronic obstructive pulmonary disease.

This meta-analysis evaluates the efficacy and safety of bacterial lysates for managing chronic obstructive pulmonary disease in adults. The study synthesizes data comparing bacterial lysates against placebo or conventional COPD therapy to determine impacts on exacerbation frequency, duration, and associated clinical symptoms.

Key findings indicate that bacterial lysates are associated with a significant reduction in the risk of exacerbations (RR 0.83; 95% CI 0.74 to 0.93) and a significant reduction in the mean number of exacerbations (MD -0.19; 95% CI -0.30 to -0.08). Additionally, the risk of hospitalization was reduced (RR 0.52; 95% CI 0.35 to 0.78). Symptom scores showed significant improvements for cough (SMD -0.37) and dyspnea (SMD -0.42). However, no statistically significant reduction was found in exacerbation duration (MD -9.26; 95% CI -19.56 to 1.03) or sputum production (SMD -0.20).

Authors noted that effects varied by formulation, and findings require confirmation in trials specific to individual formulations. Safety data showed no significant difference in adverse events (RR 0.95; 95% CI 0.86 to 1.04). These findings suggest bacterial lysates may be a viable adjunct for reducing exacerbation frequency and hospitalization risk in COPD patients, though clinical application may depend on specific product formulations.

How this fits prior evidence

This meta-analysis addresses a gap in pharmacological management for chronic obstructive pulmonary disease. While previous evidence highlighted the use of Pilates and Tai Chi for improving outcomes in COPD, and TCM as a potential adjunct for those with comorbid osteoporosis, this finding provides evidence for bacterial lysates as a potential intervention to reduce exacerbation risk and hospitalization. It does not directly relate to the reported risks of serplulimab-induced pneumonitis or the efficacy of telehealth-based pulmonary rehabilitation.

Living with chronic obstructive pulmonary disease (COPD) often means dealing with sudden, scary flare-ups that can lead to hospital stays. Researchers looked at how bacterial lysates—which are essentially mixtures of broken-down bacteria—might help manage these episodes. The study found that these lysates were linked to a lower risk of flare-ups and a lower risk of being hospitalized.

While the treatment did not significantly change how long a flare-up lasted, it did show some promise in improving symptoms like coughing and shortness of breath. However, the results were not as clear for other symptoms, such as the amount of phlegm produced. It is also important to note that the effects can vary depending on the specific type of bacterial lysate used.

Because the results vary by formulation, more specific trials are needed to confirm these findings. If you have COPD, talk to your doctor about whether these specific treatments could fit into your personal care plan.

What this means for you:
Bacterial lysates may reduce the risk of COPD flare-ups and hospitalizations, though results vary by formula.

Common questions

Can bacterial lysates help with COPD symptoms?

Yes, the study found that bacterial lysates were linked to improvements in cough and shortness of breath (dyspnoea). However, they did not show a significant change in sputum production. Because results vary based on the specific formulation used, you should talk to your doctor about which options are best for you.

Does this treatment reduce the risk of being hospitalized?

The data showed a reduction in the risk of hospitalization for adults with COPD. It also showed a reduction in the risk and the average number of flare-ups (exacerbations). These findings suggest the treatment may help keep patients out of the hospital during flare-ups.

Is it safe to use bacterial lysates for COPD?

The study reported no significant difference in adverse events between those taking bacterial lysates and those receiving standard care or a placebo. While the treatment showed a favorable safety profile in this review, you should always consult your healthcare provider before starting a new treatment.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedOct 2026
View Original Abstract ↓
Chronic obstructive pulmonary disease (COPD) with exacerbations often triggered by infections. Bacterial lysates have been investigated as interventions to reduce the exacerbations of COPD. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) evaluating bacterial lysates (BLs) in adults with chronic obstructive pulmonary disease (COPD). PubMed, EMBASE, CENTRAL, Web of Science, Google Scholar, ICTRP, and ClinicalTrials.gov were searched. In adults with COPD that compared bacterial lysates with placebo or conventional COPD therapy. Primary outcomes were the effect of BLs on exacerbations and duration. Secondary outcomes were hospitalisation risk, the mean number of exacerbations per participant during trial follow up, symptom scores for dyspnoea, sputum, cough, and adverse events. We used random-effects meta-analysis, assessed risk of bias with Cochrane RoB 2, graded certainty with GRADE. Fifteen RCTs were included. The pooled risk ratio (RR) for exacerbation in patients with COPD treated with BLs vs. control was 0.83 (95% CI 0.74–0.93; P = 0.0009). The mean difference (MD) for exacerbation duration showed no statistical significant reduction −9.26 Days (95% CI −19.56 to 1.03; P = 0.08). Mean number of exacerbations (MD) −0.19 (95% CI −0.30 to −0.08; P = 0.0009). Hospitalisation RR was 0.52 (95% CI 0.35–0.78; P = 0.001).Symptom outcomes were dyspnoea standardised mean difference (SMD) −0.42 (95% CI −0.75 to −0.10; P = 0.01), cough (SMD) −0.37 (95% CI −0.63 to −0.11; P = 0.006), while sputum production showed no significant change (SMD) −0.20 (95% CI −0.65 to 0.25; P = 0.39), The RR for adverse events was 0.95 (95% CI 0.86–1.04; P = 0.27). Bacterial lysates may be associated with lower COPD exacerbation and hospitalisation risk, with small numerical improvements in dyspnoea, cough, sputum production showed no significant improvement; effects varied by formulation, these findings require confirmation in formulation specific trials. https://www.crd.york.ac.uk/PROSPERO/view/CRD42024570783, PROSPERO CRD42024570783.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.